Better testing for central nervous system cancers
Using licensed technology based on extensive scientific research conducted at Johns Hopkins University for over 10 years, Belay has developed a proprietary molecular testing platform.
- Belay Summit™ 2.0 Comprehensive Genomic Profile detects tumor-derived nucleic acid in cerebrospinal fluid from a standard lumbar puncture.
- Unlike currently available alternatives like cytology, MRI scans, or brain biopsies, our proprietary testing offers a highly accurate, minimally invasive and comprehensive molecular profile.
- CSF cytology has low sensitivity and excludes genomic data. Imaging lacks specificity and molecular insights. Brain biopsies are challenged with insufficient tissue volume, tumor heterogeneity, and patient morbidity and mortality risk.
Introducing Belay Summit™ 2.0 Comprehensive Genomic profile
- Summit™ 2.0 is a liquid biopsy that tests patient CSF samples, thereby circumventing the blood brain barrier. Sequencing tumor-derived nucleic acid in CSF can detect genomic alterations commonly associated with CNS cancers and may ultimately preempt tumor biopsy in certain instances
- Our proprietary assay detects variants and chromosomal arm length alterations from tumor-derived nucleic acid in CSF to help inform diagnosis and management of primary and secondary brain and spinal cord malignancies
Summit™ 2.0 focuses on evaluating tumor-derived nucleic acid in CSF
With our proprietary testing, we provide a path forward to better patient care for those with CNS tumors
The future of genomic testing in CSF is here
The advances we’re introducing in the detection and management of CNS cancers represent an innovative leap in treating patients.
Introducing Belay Vantage™
- Vantage is an advanced approach to determining MGMT promoter methylation status and can be ordered concomitantly with Summit
- Vantage uses quantitative polymerase chain reaction to evaluate MGMT promoter methylation in cerebrospinal fluid of individuals with known or suspected central nervous system tumors. Analysis of CSF is less invasive than brain biopsy. Vantage can be ordered using the same patient specimen as Summit
- MGMT promoter methylation testing is recommended in all high-grade gliomas. Since MGMT status can change, this testing is a significant advancement in helping treat these patients